Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PGK1 | P00558 | 2/20 | 0.51 |
| ▸ | PGK2 | P07205 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.47 |
| ▸ | MLYCD | O95822 | 1/20 | 0.47 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6865758 | 0.85 | MEN1 (0.62) | ACP3MEN1KMT2AMAPTHTT | |
| SCHEMBL4994236 | 0.83 | ACP3 (0.51) | ACP3MEN1KMT2AMAPTHTT | |
| SCHEMBL4994252 | 0.83 | ACP3 (0.51) | ACP3MEN1KMT2AMAPTPGK1 | |
| SCHEMBL30235602 | 0.81 | MEN1 (0.66) | ACP3MEN1KMT2AMAPTHTT | |
| SCHEMBL10900761 | 0.81 | MEN1 (0.66) | ACP3MEN1KMT2AMAPTHTT | |
| SCHEMBL2407518 | 0.80 | MEN1 (0.56) | ACP3MEN1KMT2AMAPTHTT | |
| SCHEMBL6929122 | 0.80 | TAAR1 (0.57) | ACP3MEN1KMT2AMAPTHTT | |
| SCHEMBL8232750 | 0.80 | MEN1 (0.56) | ACP3MEN1KMT2AMAPTHTT | |
| SCHEMBL1295378 | 0.80 | MEN1 (0.56) | ACP3MEN1KMT2AMAPTHTT | |
| SCHEMBL8938031 | 0.79 | ACP3 (1.00) | ACP3MEN1KMT2AMAPTPGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340534-B2 | Compounds and methods for treating ocular diseases | ALLERGAN, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20160024068-A1 | COMPOUNDS AND METHODS FOR TREATING OCULAR DISEASES | ALLERGAN, INC. | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024068-A1 | COMPOUNDS AND METHODS FOR TREATING OCULAR DISEASES | ALDH1A2, PTGS1, PTGIS | ACP3 1631/4885MEN1 1926/4885KMT2A 4257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.